Phase II Study of Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer

被引：0
|
作者：
Pietanza, M. Catherine [1 ]
Travis, William D. [1 ]
Chan, Timothy A. [1 ]
Ginsberg, Michelle S. [1 ]
Kris, Andrei Holodny Mark G. [1 ]
Krug, Lee M. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
PANCREAS | 2010年 / 39卷 / 02期
关键词：
D O I：
10.1097/01.mpa.0000363940.51906.5a
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：279 / 279
页数：1
相关论文
共 50 条
  • [31] Phase II trial of vinflunine (VFL) in sensitive and refractory relapsed small-cell lung cancer (SCLC): Updated results
    Lunin, S. D.
    Spigel, D. R.
    Hainsworth, J. D.
    Waterhouse, D. M.
    Infante, J. R.
    Yardley, D. A.
    Burris, H. A., III
    Vazquez, E. R.
    Farley, C.
    Greco, F. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] A phase II study of nintedanib in patients with relapsed small cell lung cancer
    Han, Ji-Youn
    Kim, Hyae Young
    Lim, Kun Young
    Hwangbo, Bin
    Lee, Jin Soo
    LUNG CANCER, 2016, 96 : 108 - 112
  • [33] A Phase II Study of Vobramitamab Duocarmazine in Patients with Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer
    Gupta, B.
    Zaemes, J. P.
    Yeung, V.
    Reuss, J.
    Aggarwal, V.
    Thompson, J.
    Swanson, N.
    Perez, D. de Miguel
    Ahn, J.
    Chen, K.
    Veytsman, I.
    Gutierrez, M.
    Rolfo, C. D.
    Liu, S. V.
    Kim, C.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S661 - S662
  • [34] Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer
    Mori, K
    Kamiyama, Y
    Kondo, T
    Kano, Y
    Kodama, T
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (01) : 86 - 90
  • [35] Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer
    Kiyoshi Mori
    Yukari Kamiyama
    Tetsuro Kondo
    Yasuhiko Kano
    Tetsuro Kodama
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 86 - 90
  • [36] Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
    Francesco Gelsomino
    Marcello Tiseo
    Fausto Barbieri
    Ferdinando Riccardi
    Luigi Cavanna
    Antonio Frassoldati
    Angelo Delmonte
    Lucia Longo
    Claudio Dazzi
    Saverio Cinieri
    Ida Colantonio
    Francesca Sperandi
    Giuseppe Lamberti
    Stefano Brocchi
    Lorenzo Tofani
    Luca Boni
    Andrea Ardizzoni
    British Journal of Cancer, 2020, 123 : 26 - 32
  • [37] Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
    Gelsomino, Francesco
    Tiseo, Marcello
    Barbieri, Fausto
    Riccardi, Ferdinando
    Cavanna, Luigi
    Frassoldati, Antonio
    Delmonte, Angelo
    Longo, Lucia
    Dazzi, Claudio
    Cinieri, Saverio
    Colantonio, Ida
    Sperandi, Francesca
    Lamberti, Giuseppe
    Brocchi, Stefano
    Tofani, Lorenzo
    Boni, Luca
    Ardizzoni, Andrea
    BRITISH JOURNAL OF CANCER, 2020, 123 (01) : 26 - 32
  • [38] Phase 2 Study of Aldoxorubicin versus Topotecan for Relapsed/Refractory Small Cell Lung Cancer
    Chawla, Shanta
    Wieland, Scott
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S742 - S742
  • [39] PHASE 2 STUDY OF ALDOXORUBICIN VERSUS TOPETECAN FOR RELAPSED/REFRACTORY SMALL CELL LUNG CANCER
    Wieland, S.
    Mita, A.
    Piantadosi, S.
    Natale, R.
    Levitt, D.
    ANNALS OF ONCOLOGY, 2014, 25
  • [40] Phase II study of NK012 in relapsed small cell lung cancer
    Raefsky, E.
    Spigel, D. R.
    Infante, J. R.
    Bendell, J. C.
    Jones, S. F.
    Lipman, A. J.
    Trent, D.
    Kawamura, S.
    Greco, F. A.
    Hainsworth, J. D.
    Burris, H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345